BRPI0415939A - composições de um inibidor seletivo da ciclooxigenase-2 e um agente de modulação do fator neurotrófico para o tratamento de distúrbios mediados pelo sistema nervoso central - Google Patents

composições de um inibidor seletivo da ciclooxigenase-2 e um agente de modulação do fator neurotrófico para o tratamento de distúrbios mediados pelo sistema nervoso central

Info

Publication number
BRPI0415939A
BRPI0415939A BRPI0415939-0A BRPI0415939A BRPI0415939A BR PI0415939 A BRPI0415939 A BR PI0415939A BR PI0415939 A BRPI0415939 A BR PI0415939A BR PI0415939 A BRPI0415939 A BR PI0415939A
Authority
BR
Brazil
Prior art keywords
nervous system
central nervous
inhibitor
compositions
treatment
Prior art date
Application number
BRPI0415939-0A
Other languages
English (en)
Inventor
Duncan P Taylor
Diane T Stephenson
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of BRPI0415939A publication Critical patent/BRPI0415939A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçõES DE UM INIBIDOR SELETIVO DA CICLOOXIGENASE-2 E UM AGENTE DE MODULAçãO DO FATOR NEUROTRóFICO PARA O TRATAMENTO DE DISTúRBIOS MEDIADOS PELO SISTEMA NERVOSO CENTRAL". A presente invenção refere-se a composições e métodos para o tratamento de distúrbios mediados pelo sistema nervoso central. Mais particularmente, a invenção refere-se a uma terapia de combinação para o tratamento de um distúrbio mediado pelo sistema nervoso central compreendendo a administração a um indivíduo de um agente de modulação do fator neurotrófico em combinação com um inibidor seletivo da ciclooxigenase-2.
BRPI0415939-0A 2003-11-12 2004-11-12 composições de um inibidor seletivo da ciclooxigenase-2 e um agente de modulação do fator neurotrófico para o tratamento de distúrbios mediados pelo sistema nervoso central BRPI0415939A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51947103P 2003-11-12 2003-11-12
PCT/US2004/037882 WO2005046615A2 (en) 2003-11-12 2004-11-12 Compositions for treatment of central nervous system mediated disorders

Publications (1)

Publication Number Publication Date
BRPI0415939A true BRPI0415939A (pt) 2007-01-02

Family

ID=34590419

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415939-0A BRPI0415939A (pt) 2003-11-12 2004-11-12 composições de um inibidor seletivo da ciclooxigenase-2 e um agente de modulação do fator neurotrófico para o tratamento de distúrbios mediados pelo sistema nervoso central

Country Status (6)

Country Link
US (1) US20050148589A1 (pt)
EP (1) EP1684784A2 (pt)
JP (1) JP2007510756A (pt)
BR (1) BRPI0415939A (pt)
CA (1) CA2545731A1 (pt)
WO (1) WO2005046615A2 (pt)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126563T2 (de) * 1990-04-12 1998-02-05 Ebewe Arzneimittel Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia
US5544347A (en) * 1990-09-24 1996-08-06 Emc Corporation Data storage system controlled remote data mirroring with respectively maintained data indices
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5447939A (en) * 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
AU7491396A (en) * 1995-10-25 1997-05-15 Janssen Pharmaceutica N.V. Infusions of neuroprotectants and thrombolytic agents
ATE233743T1 (de) * 1996-04-12 2003-03-15 Searle & Co N-((4-(5-methyl-3-phenylisoxazol-4- yl)phenyl)sulphonylpropylamid und sein natriumsalz als pro-pharmakon von cox-2 inhibitoren
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6145066A (en) * 1997-11-14 2000-11-07 Amdahl Corporation Computer system with transparent data migration between storage volumes
US6820098B1 (en) * 2002-03-15 2004-11-16 Hewlett-Packard Development Company, L.P. System and method for efficient and trackable asynchronous file replication
US7225204B2 (en) * 2002-03-19 2007-05-29 Network Appliance, Inc. System and method for asynchronous mirroring of snapshots at a destination using a purgatory directory and inode mapping
US20040143639A1 (en) * 2002-06-28 2004-07-22 Venkat Rangan Apparatus and method for data replication in a storage processing device
US7260739B2 (en) * 2003-05-09 2007-08-21 International Business Machines Corporation Method, apparatus and program storage device for allowing continuous availability of data during volume set failures in a mirrored environment
US7111139B2 (en) * 2004-03-02 2006-09-19 Hitachi, Ltd. Data synchronization of multiple remote storage
US7617365B2 (en) * 2004-04-28 2009-11-10 Emc Corporation Systems and methods to avoid deadlock and guarantee mirror consistency during online mirror synchronization and verification
US7225307B2 (en) * 2004-05-04 2007-05-29 International Business Machines Corporation Apparatus, system, and method for synchronizing an asynchronous mirror volume using a synchronous mirror volume

Also Published As

Publication number Publication date
WO2005046615A2 (en) 2005-05-26
JP2007510756A (ja) 2007-04-26
EP1684784A2 (en) 2006-08-02
WO2005046615A3 (en) 2006-06-22
CA2545731A1 (en) 2005-05-26
US20050148589A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0415397A (pt) métodos e reagentes para o tratamento de desordens imunoinflamatórias
BRPI0410041A (pt) métodos para tratamento de dor de cabeça de sinusite
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
EA200970791A1 (ru) N-АДАМАНТИЛБЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 11-β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
DOP2007000015A (es) Usos terapéuticos de inhibidores de rtp801
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
ECSP045021A (es) Terapia de combinacion para el tratamiento del cancer
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BRPI0411174A (pt) combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão
BRPI0411175A (pt) combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão
CY1110368T1 (el) Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη
BRPI0413679A (pt) formulações de um inibidor seletivo da ciclooxigenase-2 e de um agente de modulação da serotonina para o tratamento da neoplasia
BRPI0415939A (pt) composições de um inibidor seletivo da ciclooxigenase-2 e um agente de modulação do fator neurotrófico para o tratamento de distúrbios mediados pelo sistema nervoso central
DE60321953D1 (de) Neue synergistische zusammensetzung enthaltend roflumilast und formoterol
NO20051159L (no) Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein
WO2005018541A3 (en) Cox-2 inhibitor and serotonin modulator for treating cns damage
BRPI0410305A (pt) composições de um inibidor seletivo de ciclooxigenase-2 á base de benzenossulfonamida ou metilsulfonilbenzeno e um agente colinérgico para o tratamento de redução de fluxo sangüìneo ou traumatismo do sistema nervoso central
BRPI0410287A (pt) composições para o tratamento de fluxo sanguìneo reduzido
BRPI0514303A (pt) composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2005016243A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]